Instrument Inactif

Autres langues TapImmune Inc. OTC Bulletin Board

Actions

TPIV

US8760334081

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	15/05
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	15/05
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	08/04
North American Morning Briefing : Stocks Edge -2-	27/03
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	25/03
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	22/03
North American Morning Briefing : Markets on Hold -2-	20/03
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	22/01
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	22/01
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	21/12
Top Midday Gainers	11/12
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	11/12
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	11/12
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	09/11
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TapImmune Inc. OTC Bulletin Board

Actions

TPIV

US8760334081

Autres langues

Filtres